Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.

NCT00390624 is registered in ClinicalTrials.gov with Rocky Mountain Cancer Centers as lead sponsor.

NCT NCT00390624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.
Lead sponsor
Rocky Mountain Cancer Centers
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2003
Completion date
December 31, 2006
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute renal failure, mortality, renal dysfunction